ClinicalTrials.gg

Program

BEBT-109

A development code. Also written as “BEBT-109 Capsules” and “BEBT-109 Capsule”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by BeBetter Med.

Furthest: phase 2, since Jul 17, 20242 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeBetter Med22 open or runningphase 2since Jul 17, 2024Jul 17, 2024Jun 2027phase 2 · NCT06514027

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 17, 2024First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06514027 · 30 planned · China
  2. Nov 25, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06706713 · 200 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06514027

TargetBeta

EGFR →read by rule
“Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC With EGFR Exon 20 Insertion Mutations: a Phase 1B, Dose Escalation and Expansion Trial”study text, by rule · the study

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06706713Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 31, 2025200
NCT06514027Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 202730

How it is read

Names in the registry

  • “BEBT-109 Capsules”, 1 entry
  • “BEBT-109 Capsule”, 1 entry

Codes read as this program: BEBT109.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.